Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Lymecycline→

Lymecycline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
992-21-2
Molecular formula
C29H38N4O10
Molecular weight
602.6 g/mol
Drug class
Tetracycline-class antibacterial antibiotic
Mechanism of action
Bacteriostatic agent that binds the bacterial 30S ribosomal subunit and prevents aminoacyl-tRNA access to the mRNA–ribosome complex, inhibiting protein synthesis. In acne, part of the effect is due to reduced growth of susceptible skin organisms and reduced free fatty acids in sebum.
Indications / reported uses
  • Moderate-to-severe acne vulgaris
  • Infections caused by tetracycline-sensitive organisms, including selected respiratory, urogenital (Chlamydia), soft-tissue and rickettsial infections; use is subject to official antimicrobial guidance and product-specific indication

Sources: UK SmPC — Lymecycline 408 mg capsules · UK SmPC — Tetralysal 300 mg capsules (updated 12 Aug 2026) · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Tetracycline-class antibacterial antibiotic

Mechanism of action

Bacteriostatic agent that binds the bacterial 30S ribosomal subunit and prevents aminoacyl-tRNA access to the mRNA–ribosome complex, inhibiting protein synthesis. In acne, part of the effect is due to reduced growth of susceptible skin organisms and reduced free fatty acids in sebum.

General use cases

  • Moderate-to-severe acne vulgaris
  • Infections caused by tetracycline-sensitive organisms, including selected respiratory, urogenital (Chlamydia), soft-tissue and rickettsial infections; use is subject to official antimicrobial guidance and product-specific indication

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Lymecycline Environmental Risk Assessment (ERA) (the Lymecycline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.